These findings establish FOXD1–AS1 as a central driver of GC progression and chemoresistance, operating through a PI3K/AKT/mTOR‐dependent mechanism involving translational regulation and miRNA sequestration. This evidence concerns the gene FOXD1 and gastric cancer.